Hetrombopag Combined With rhTPO for Cancer Therapy-induced Thrombocytopenia

Phase 2, randomised, open-label trial of recombinant human thrombopoietin in Thrombocytopenia (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Proportion of patients achieving PLT >=100x10^9/L or an increase >=50x10^9/L from baseline at 14 days. Planned start Jan 2026; status: not yet recruiting.